H-plk Inhibitors

H-plk inhibitors are chemical compounds that specifically aim to alter the functional activity of the cell division protein, H-plk, which plays a critical role in the regulation of mitosis. One such inhibitor, BI 2536, exhibits its inhibitory action by directly binding to the ATP-binding pocket of H-plk, thereby halting the cell cycle and inducing apoptosis. Similarly, Volasertib and GSK461364 are selective inhibitors that target H-plk, leading to mitotic arrest by preventing spindle assembly and cytokinesis or inhibiting kinase activity, respectively. The action of these inhibitors results in the disruption of cancer cell proliferation due to their ability to arrest cell cycle progression.

Additionally, molecules like ON-01910 (Rigosertib) and TAK-960 interfere with H-plk functions such as mitotic spindle assembly and mitotic progression. ON-01910 does so in a non-ATP-competitive manner, while TAK-960 is known for its potent and selective inhibition of H-plk, leading to cell cycle arrest. Other compounds, such as SBE13 and HMN-176, achieve indirect inhibition by stabilizing the spindle assembly checkpoint and altering the intracellular localization and function of H-plk, respectively. Compounds like ZK-thiazolidinone and Cyclapolin 9 interfere with H-plk by targeting its polo-box domain, essential for its localization and function. Indirect inhibitors such as LFM-A13, Purvalanol A, and Wortmannin downregulate H-plk activity by interfering with related pathways like the JAK2/STAT pathway and the PI3K/AKT pathway, further illustrating the diverse mechanisms by which H-plk activity can be dampened.